Gibtulio 10mg Tablet contains Empagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated for the management of type 2 diabetes mellitus. By inhibiting SGLT2 in the proximal renal tubules, Empagliflozin reduces glucose reabsorption and increases urinary glucose excretion, thereby lowering plasma glucose levels. This mechanism is independent of insulin secretion or action, making it effective as monotherapy or in combination with other antidiabetic agents. Gibtulio 10mg is prescribed to improve glycemic control in adults with type 2 diabetes, particularly in patients with inadequate response to diet and exercise alone. Clinical studies have demonstrated that Empagliflozin also contributes to modest weight reduction and blood pressure lowering, providing additional cardiovascular benefits. The recommended dose is 10 mg once daily, with or without food. Caution is advised in patients with renal impairment, as efficacy diminishes with declining kidney function. Common adverse effects include urinary tract infections, genital mycotic infections, and increased urination. Patients should be monitored for signs of ketoacidosis, dehydration, and electrolyte imbalances. Gibtulio should be used under medical supervision, with regular monitoring of glycemic status and renal function to ensure optimal therapeutic outcomes.